文献速递血脂与心血管预防

心脏肌钙蛋白与心血管疾病风险预测:个体参与者数据荟萃分析

Cardiac Troponins and Cardiovascular Disease Risk Prediction: An Individual-Participant-Data Meta-Analysis.
PubMed 文献 · J Am Coll Cardiol · 2025-01-01

该研究基于15个队列、62,150名无既往心血管疾病的个体参与者数据,分析将高敏肌钙蛋白T或I加入传统风险因素后对首发心血管疾病的预测价值。结果显示,肌钙蛋白T或I每升高1个标准差,心血管疾病风险比分别为1.31和1.26,C指数小幅提升0.015和0.012,连续净重分类改善在病例中为6%和5%,在非病例中为22%和17%。

要点

  • 肌钙蛋白T或I每升高1个标准差,首发心血管疾病风险分别增加31%和26%。
  • 加入肌钙蛋白T或I后,C指数仅提升0.015和0.012,预测改善幅度有限。
  • 肌钙蛋白T或I使中危重分类为高危者中,每筛查408人或473人可预防1例额外事件。

核心结论

  • 测量心脏肌钙蛋白对首发心血管疾病预测有适度改善,大规模应用可能带来人群健康获益。

研究设计与样本

  • 个体参与者数据荟萃分析,纳入15个队列共62,150名无既往心血管疾病的参与者。
  • 计算将肌钙蛋白T或I加入传统风险因素后的风险比、风险判别指标和重分类改善。

主要发现

  • 肌钙蛋白T测量组中位随访11.8年发生8,133例首发心血管事件,肌钙蛋白I组中位随访9.8年发生3,749例。
  • 肌钙蛋白T每升高1个标准差的心血管疾病风险比为1.31(95% CI: 1.25-1.37),肌钙蛋白I为1.26(95% CI: 1.19-1.33)。
  • 加入肌钙蛋白T或I后C指数分别增加0.015(95% CI: 0.012-0.018)和0.012(95% CI: 0.009-0.015)。
  • 连续净重分类改善在病例中分别为6%和5%,在非病例中分别为22%和17%。
  • 基于他汀治疗,肌钙蛋白T或I测量使中危重分类为高危者中,每筛查408人或473人可预防1例额外心血管事件。

关键数值与推荐

  • 肌钙蛋白T每升高1个标准差的心血管疾病风险比为1.31(95% CI: 1.25-1.37)。
  • 肌钙蛋白I每升高1个标准差的心血管疾病风险比为1.26(95% CI: 1.19-1.33)。
  • 加入肌钙蛋白T或I后C指数增加分别为0.015(95% CI: 0.012-0.018)和0.012(95% CI: 0.009-0.015)。
  • 连续净重分类改善在病例中为6%和5%,在非病例中为22%和17%。
  • 肌钙蛋白T或I测量使中危重分类为高危者中,每筛查408人或473人可预防1例额外心血管事件。

临床怎么用

  • 对于传统风险因素评估为中危的个体,可考虑检测高敏肌钙蛋白T或I以辅助风险重分类。
  • 肌钙蛋白T或I测量有助于识别可能从他汀治疗中获益更多的中危个体。
  • 肌钙蛋白预测改善幅度有限,不应替代传统风险因素评估。

局限性

  • 研究未报告各队列的具体特征和肌钙蛋白检测方法细节,可能影响结果的外推性。
  • 建模他汀治疗获益基于英国人群发病率数据,其他人群的适用性需进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The extent to which high-sensitivity cardiac troponin can predict cardiovascular disease (CVD) is uncertain. OBJECTIVES: We aimed to quantify the potential advantage of adding information on cardiac troponins to conventional risk factors in the prevention of CVD. METHODS: We meta-analyzed individual-participant data from 15 cohorts, comprising 62,150 participants without prior CVD. We calculated HRs, measures of risk discrimination, and reclassification after adding cardiac troponin T (cTnT) or I (cTnI) to conventional risk factors. The primary outcome was first-onset CVD (ie, coronary heart disease or stroke). We then modeled the implications of initiating statin therapy using incidence rates from 2.1 million individuals from the United Kingdom. RESULTS: Among participants with cTnT or cTnI measurements, 8,133 and 3,749 incident CVD events occurred during a median follow-up of 11.8 and 9.8 years, respectively. HRs for CVD per 1-SD higher concentration were 1.31 (95% CI: 1.25-1.37) for cTnT and 1.26 (95% CI: 1.19-1.33) for cTnI. Addition of cTnT or cTnI to conventional risk factors was associated with C-index increases of 0.015 (95% CI: 0.012-0.018) and 0.012 (95% CI: 0.009-0.015) and continuous net reclassification improvements of 6% and 5% in cases and 22% and 17% in noncases. One additional CVD event would be prevented for every 408 and 473 individuals screened based on statin therapy in those whose CVD risk is reclassified from intermediate to high risk after cTnT or cTnI measurement, respectively. CONCLUSIONS: Measurement of cardiac troponin results in a modest improvement in the prediction of first-onset CVD that may translate into population health benefits if used at scale.

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Shah ASV, Keene SJ, Pennells L, et al. Cardiac Troponins and Cardiovascular Disease Risk Prediction: An Individual-Participant-Data Meta-Analysis. J Am Coll Cardiol. 2025. PMID: 40204376. doi:10.1016/j.jacc.2025.02.016

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。